Internal medicine

Medicine & Life Sciences

1. Melanoma 100%
2. Coronavirus 60%
3. Dendritic Cells 58%
4. Belgium 57%
5. pembrolizumab 56%
6. Ipilimumab 55%
7. HIV 49%
8. Therapeutics 46%
9. Nivolumab 44%
10. Clinical Trials, Phase I 39%
11. talimogene laherparepvec 38%
12. HIV-1 37%
13. trametinib 35%
14. dabrafenib 35%
15. Neoplasms 34%
16. avelumab 34%
17. Myeloid Cells 33%
18. Continuous Renal Replacement Therapy 30%
19. Glioblastoma 28%
20. Safety 26%
21. Vaccines 26%
22. Immunotherapy 25%
23. Type 1 Diabetes Mellitus 25%
24. Phase II Clinical Trials 24%
25. Vaccination 23%
26. Islets of Langerhans 23%
27. Survival 22%
28. trimix 21%
29. Clinical Trials 21%
30. T-Lymphocytes 21%
31. SARS Virus 20%
32. Anti-Bacterial Agents 20%
33. Infections 19%
34. Tumor Burden 19%
35. Superinfection 18%
36. Systematic Reviews 18%
37. Pandemics 18%
38. Frailty 17%
39. Brugada Syndrome 17%
40. HIV Infections 17%
41. Thyroid Gland 16%
42. Pharmaceutical Preparations 16%
43. Severe Acute Respiratory Syndrome 16%
44. Fatigue 15%
45. Multiple Myeloma 15%
46. Biomarkers 15%
47. Mitogen-Activated Protein Kinase Kinases 15%
48. Messenger RNA 15%
49. Injections 14%
50. Axitinib 14%
51. Viruses 14%
52. Standard of Care 14%
53. Non-Small Cell Lung Carcinoma 14%
54. Retrospective Studies 14%
55. Population 13%
56. Fluorodeoxyglucose F18 13%
57. Lactams 13%
58. Mutation 13%
59. Survivors 12%
60. Cohort Studies 12%
61. Guidelines 12%
62. Recurrence 12%
63. Respiratory Tract Infections 12%
64. University Hospitals 12%
65. Catheters 12%
66. Hospitalization 12%
67. Neoplasm Metastasis 12%
68. Insulin 11%
69. Pancreas 11%
70. Disease Outbreaks 11%
71. Omentum 11%
72. Brain 11%
73. Skin 11%
74. heparin-binding hemagglutinin 11%
75. Glucose 11%
76. Delivery of Health Care 11%
77. Lymphadenopathy 10%
78. Antibodies 10%
79. Single-Domain Antibodies 10%
80. Transplants 10%
81. Cardiac Arrhythmias 10%
82. Fever 10%
83. Rilpivirine 10%
84. Viral Load 10%
85. Immunity 10%
86. Liver 9%
87. dolutegravir 9%
88. Quality of Life 9%
89. Ventilator-Associated Pneumonia 9%
90. Familial Hypophosphatemic Rickets 9%
91. Pneumonia 9%
92. Activities of Daily Living 9%
93. Tsunamis 9%
94. Blocking Antibodies 9%
95. Observational Studies 9%
96. Human Influenza 9%
97. Natural Killer T-Cells 9%
98. Serum 9%
99. RNA 9%
100. Programmed Cell Death 1 Receptor 9%